AGIO

Agios Pharmaceuticals, Inc.

AGIO | $31.82 5.33% 5.06% 1.2M

(0.0% 1d) (7.2% 1m) (41.8% 1y) (0.0% 2d) (5.3% 3d) (9.1% 7d) (42.2% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 1,788,120,032
http://www.agios.com
Sec Filling | Patents | 536 employees

(US) Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

skin cancer genetic

Drugs

Tibsovo (ivosidenib)

add to watch list Paper trade email alert is off

Press-releases

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| 10.03% | O: 0.83% H: 0.0% C: 0.0%
first conference financial results

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Published: 2024-04-09 (Crawled : 11:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| 13.0% | O: -1.1% H: 7.24% C: 6.72%
report

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| -1.12% | O: -0.65% H: 0.94% C: -1.85%
biopharma global

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
Published: 2024-02-22 (Crawled : 12:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| 18.69% | O: -0.26% H: 12.4% C: 11.41%
conference health care

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Published: 2024-02-15 (Crawled : 12:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| 22.82% | O: -3.75% H: 8.3% C: 7.5%
business year financial results

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| 38.55% | O: -1.57% H: 3.01% C: 2.17%
conference year financial results

Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period (2019-2032), Evaluates DelveInsight | Leading Companies - Vertex Pharmaceuticals, CRISPR Therapeutics, Agios Pharmaceuticals, Celgene, Forma Therapeutics
Published: 2024-01-17 (Crawled : 22:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 20.58% | O: -0.36% H: 1.32% C: 1.18%
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -6.62% | O: -0.21% H: 0.0% C: 0.0%
VRTX | $404.93 1.25% 1.43% 1.1M

Health Technology

| -6.65% | O: -0.5% H: 0.76% C: 0.32%
EDIT | News | $5.465 -2.41% -2.47% 1.6M

Health Technology

| -35.08% | O: 0.83% H: 0.35% C: -3.66%
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| 46.52% | O: 0.41% H: 0.0% C: -2.2%
crispr companies therapeutics growth study market

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| 37.47% | O: -0.43% H: 6.16% C: 6.12%
rare disease key

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Published: 2024-01-02 (Crawled : 12:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| 42.84% | O: -0.31% H: 4.59% C: 2.84%
conference

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
Published: 2023-12-10 (Crawled : 00:20) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M

Health Technology

| Email alert Add to watchlist
disease positive cell meeting results study

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001439222-24-000058	4	2024-03-07	2024-03-06	Sell	S	4415	6809
0001439222-24-000058	4	2024-03-07	2024-03-05	Sell	S	300	11224
0001439222-24-000056	4	2024-03-07	2024-03-05	Sell	S	1913	2886